During the last session, Jasper Therapeutics Inc (NASDAQ:JSPR)’s traded shares were 0.44 million, with the beta value of the company hitting 2.19. At the end of the trading day, the stock’s price was $19.27, reflecting an intraday loss of -8.63% or -$1.82. The 52-week high for the JSPR share is $31.01, that puts it down -60.92 from that peak though still a striking 66.27% gain since the share price plummeted to a 52-week low of $6.50. The company’s market capitalization is $289.08M, and the average intraday trading volume over the past 10 days was 0.22 million shares, and the average trade volume was 263.07K shares over the past three months.
Jasper Therapeutics Inc (JSPR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. JSPR has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it.
Jasper Therapeutics Inc (NASDAQ:JSPR) trade information
Jasper Therapeutics Inc (JSPR) registered a -8.63% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.63% in intraday trading to $19.27, hitting a weekly high. The stock’s 5-day price performance is -14.36%, and it has moved by -18.42% in 30 days. Based on these gigs, the overall price performance for the year is 175.68%. The short interest in Jasper Therapeutics Inc (NASDAQ:JSPR) is 2.07 million shares and it means that shorts have 10.97 day(s) to cover.
The consensus price target of analysts on Wall Street is $63, which implies an increase of 69.41% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $63 and $63 respectively. As a result, JSPR is trading at a discount of -226.93% off the target high and -226.93% off the low.
Jasper Therapeutics Inc (JSPR) estimates and forecasts
Statistics show that Jasper Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Jasper Therapeutics Inc (JSPR) shares have gone down -8.85% during the last six months, with a year-to-date growth rate more than the industry average at 27.51% against 16.80.
While earnings are projected to return 27.23% in 2025.
JSPR Dividends
Jasper Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Jasper Therapeutics Inc (NASDAQ:JSPR)’s Major holders
Jasper Therapeutics Inc insiders own 1.28% of total outstanding shares while institutional holders control 98.74%, with the float percentage being 100.02%.
